TY - JOUR T1 - [Translated article] Use of Intravenous Immunoglobulins and Systemic Corticosteroids in Patients With Toxic Epidermal Necrolysis: Experience of a Hospital in Mexico City JO - Actas Dermo-Sifiliográficas T2 - AU - Barrera-Ochoa,C.A. AU - Marioni-Manríquez,S. AU - Cortázar-Azuaje,A.M. AU - Quijada-Ucelo,Z.M. AU - Saba-Mussali,A.J. AU - Vega-Memije,M.E. SN - 00017310 M3 - 10.1016/j.ad.2022.02.021 DO - 10.1016/j.ad.2022.02.021 UR - https://actasdermo.org/es-translated-article-use-intravenous-immunoglobulins-articulo-S0001731022001478 AB - Toxic epidermal necrolysis is the most serious mucocutaneous adverse drug reaction. Multidisciplinary treatment and withdrawal of the causative drug are key to reducing mortality. Few studies have analyzed the use of systemic corticosteroids and intravenous immunoglobulins (IVIG) in patients with toxic epidermal necrolysis in Latin America. We describe our experience with 6 cases treated at a dermatology referral hospital in Mexico City. None of the patients died or developed complications in the short or medium term. The most widely used regimen was a combination of IVIG 1g/kg for 3–5 days and methylprednisolone 1g for 3–5 days. Mean hospital stay was 14.8 days. The combined use of systemic corticosteroids and IVIG seems to be a safe treatment option for patients with toxic epidermal necrolysis. ER -